Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2023 Publisher: Ennogen Healthcare Ltd, Unit G4, Riverside Industrial Estate, Riverside Way, Dartford, DA1 5BS, UK
UNIPHYLLIN CONTINUS 200mg prolonged release tablets.
| Pharmaceutical Form |
|---|
|
Prolonged release tablet. White, capsule shaped tablet, plain on one side and marked ‘U200’ on the other. |
Each prolonged-release tablet contains 200 mg theophylline as 220 mg theophylline monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Theophylline |
Theophylline is a bronchodilator. In addition it affects the function of a number of cells involved in the inflammatory processes associated with asthma and chronic obstructive airways disease. Theophylline stimulates the myocardium and produces a diminution of venous pressure in congestive heart failure leading to marked increase in cardiac output. |
| List of Excipients |
|---|
|
Hydroxyethylcellulose |
Blister packs consisting of aluminium foil sealed to 250 µ m PVC with a PVdC coating of at least 40 gsm thickness, containing 8 or 56 tablets.
Polypropylene containers containing 60, 100, 250 or 1000 tablets.
Amber glass bottles containing 50 or 100 tablets.
Not all pack sizes may be marketed.
Ennogen Healthcare Ltd, Unit G4, Riverside Industrial Estate, Riverside Way, Dartford, DA1 5BS, UK
PL 40739/0328
23 August 1979 / 15 May 2003
| Drug | Countries | |
|---|---|---|
| UNIPHYLLIN | Cyprus, Ireland, Malta, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
